Physician profile
Danlin J Fuller
NPI 1407276769
$1,073.28
in general payments reported to CMS, 2019-2025
15 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.38 · 2020: $16.15 · 2021: $11.19 · 2022: $177 · 2023: $174 · 2024: $269 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $303.06 | 2022-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $167.05 | 2019-2025 | Cequa |
| Abbvie INC. | $145.83 | 2022-2024 | |
| Vertex Pharmaceuticals Incorporated | $120.32 | 2025 | |
| Rxsight INC | $93.10 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Vision Care, INC. | $45.95 | 2024 | |
| Bausch & Lomb Americas INC. | $41.58 | 2024 | Miebo, Xiidra |
| Harrow Eye, LLC | $27.04 | 2025 | Vevye |
| Dompe US, INC. | $24.41 | 2025 | Oxervate |
| Astellas Pharma US INC | $23.69 | 2025 | Izervay |
| Alcon Vision LLC | $22.86 | 2025 | Precision 1 |
| Novartis Pharmaceuticals Corporation | $16.51 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.15 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $14.54 | 2025 | Xdemvy |
| Allergan, INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danlin Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.